Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16486773 | 1.00 | ACKR3 (0.46) | ACKR3FAAHKDM1ATBK1PKM | |
| SCHEMBL2619093 | 0.87 | KDM1A (0.54) | KDM1ATBK1PKMNR1H2HDAC1 | |
| SCHEMBL16486820 | 0.84 | FAAH (0.47) | ACKR3FAAHKDM1AATMALDH1A1 | |
| SCHEMBL30525131 | 0.83 | MEN1 (0.53) | FAAHTBK1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL1020384 | 0.83 | MEN1 (0.53) | FAAHTBK1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL13985662 | 0.82 | ADORA2B (0.49) | KDM1ATBK1GPR119VEGFAEGLN1 | |
| SCHEMBL15205904 | 0.82 | GPR119 (0.43) | TBK1GPR119VEGFAEGLN1ALDH1A1 | |
| SCHEMBL16346589 | 0.82 | HDAC1 (0.58) | NR1H2HDAC1HDAC6VEGFAEGLN1 | |
| SCHEMBL28052878 | 0.82 | ACKR3 (0.44) | ACKR3FAAHKDM1AATMALDH1A1 | |
| SCHEMBL209719 | 0.80 | GPR119 (0.47) | TBK1GPR119VEGFAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
| CN-114286820-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | ACKR3 260/4885FAAH 1269/4885KDM1A 1208/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | ACKR3 260/4885FAAH 1269/4885KDM1A 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.